Bli medlem
Bli medlem

Du är här


Xvivo Perfusion: Share warrant program fully subscribed

XVIVO Perfusion AB's share warrant program 2014/2016 is fully
subscribed. A total of 195,000 warrants with the right to subscribe
for new shares were issued. Each warrant has in June 2016 the right
to subscribe for one new share at a price of SEK 58.60.

The annual shareholder meeting April 29, 2014 approved the warrant
program of a maximum of 195,000 warrants to be offered to all
employees in XVIVO Perfusion AB. Upon full exercise of the warrants,
the share capital increase is SEK 5,000 corresponding to a dilution
of about 1 percent of the total number of shares and votes.

Magnus Nilsson, CEO of XVIVO Perfusion: "The broad support is very
encouraging and it gives all of our employees a stronger shareholder
interest and an even stronger incentive to fulfill our goals."

July 7, 2014
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,

For further information on XVIVO Perfusion's business, please refer to
the company's website,

The information was submitted for publication on July 7, 2014 at 8:30

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in the USA. The XVIVO share is listed on NASDAQ OMX First North and
has the ticker symbol XVIVO. More information can be found on the
website The Certified Adviser is Redeye,


XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.